Key Points
- CTO Raymond Woo sold 4,887 CeriBell shares at an average $26.96 each, worth about $131,754. He retained 203,118 shares after the sale, a 2.35% reduction in his position.
- CeriBell’s quarterly revenue of $29.34 million slightly exceeded expectations, but its loss of $0.55 per share was wider than the $0.51 consensus estimate.
- Analyst sentiment is broadly positive: the stock has a “Moderate Buy” consensus rating and a $31.25 average price target, while Canaccord and TD Cowen each raised their target to $33.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CTO Raymond Woo sold 4,887 shares of CeriBell stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $26.96, for a total value of $131,753.52. Following the completion of the sale, the chief technology officer directly owned 203,118 shares in the company, valued at approximately $5,476,061.28. The trade was a 2.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Raymond Woo also recently made the following trade(s):
- On Thursday, October 1st, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.38, for a total value of $119,145.06.
- On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The shares were sold at an average price of $24.33, for a total value of $118,900.71.
- On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total transaction of $47,535.58.
CeriBell Trading Down 3.1%
CBLL stock opened at $27.39 on Thursday. The firm has a fifty day moving average price of $25.13 and a 200 day moving average price of $20.87. CeriBell, Inc. has a fifty-two week low of $10.94 and a fifty-two week high of $28.89. The firm has a market cap of $1.05 billion, a PE ratio of -14.12 and a beta of 0.86. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.
CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). CeriBell had a negative net margin of 67.96% and a negative return on equity of 50.37%. The business had revenue of $29.34 million for the quarter, compared to analysts' expectations of $29.18 million. Sell-side analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the stock. Canaccord Genuity Group boosted their target price on shares of CeriBell from $26.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday. Barclays raised shares of CeriBell to a "neutral" rating in a report on Tuesday, August 18th. BTIG Research reiterated a "buy" rating on shares of CeriBell in a research report on Wednesday. TD Cowen boosted their price objective on CeriBell from $29.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, October 2nd. Finally, Weiss Ratings upgraded CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $31.25.
Read Our Latest Research Report on CeriBell
CeriBell News Roundup
Here are the key news stories impacting CeriBell this week:
- Positive Sentiment: Canaccord Genuity raised its price target to $33 from $26 and maintained a Buy rating, signaling confidence in potential upside. Read More.
- Positive Sentiment: Q3 revenue of $29.34 million narrowly topped analyst expectations of $29.18 million, indicating continued sales growth. Read More.
- Neutral Sentiment: CTO Raymond Woo sold 4,887 shares for about $132,000, a 2.35% reduction in his holdings; he retained 203,118 shares afterward. Read More.
- Negative Sentiment: The company reported a quarterly loss of $0.55 per share, wider than the cited consensus estimate of $0.51, while its net loss increased year over year. New-launch expenses contributed to the higher loss, potentially keeping pressure on profitability despite the revenue beat. Read More.
Institutional Trading of CeriBell
Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in CeriBell during the second quarter worth $37,657,000. Bank of New York Mellon Corp bought a new position in CeriBell during the second quarter valued at $17,437,000. TimesSquare Capital Management LLC purchased a new stake in shares of CeriBell in the second quarter valued at $15,182,000. KCM Capital Inc raised its stake in shares of CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company's stock valued at $25,662,000 after acquiring an additional 400,000 shares during the period. Finally, Bank of America Corp DE purchased a new stake in shares of CeriBell in the second quarter valued at $4,619,000.
About CeriBell
(
Get Free Report)
CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.
The company's primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
